Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins

Oncogenesis

Volumn 5, Issue 2, 2016, Pages

  Jung, O ^a,b   Trapp Stamborski, V ^a,d   Purushothaman, A ^c   Jin, H ^a   Wang, H ^a   Sanderson, R D ^c   Rapraeger, A C ^a,b  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Alabama at Birmingham   (United States)

^d BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85099615815     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/ONCSIS.2016.5     Document Type: Article

References (100)

1. Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells 1995; 13(Suppl 2): 1–9.
2. Laubach JP, Richardson PG, Anderson KC. The evolution and impact of therapy in multiple myeloma. Med Oncol 2010; 27(Suppl 1): S1–S6.
3. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 2010; 277: 3890–3903.
4. Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem Sci 2009; 34: 511–519.
5. Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 2002; 12: 121–129.
6. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL et al. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J 2013; 280: 2294–2306.
7. Levy-Adam F, Ilan N, Vlodavsky I. Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 2010; 20: 153–160.
8. Khotskaya YB, Dai Y, Ritchie JP, MacLeod V, Yang Y, Zinn K et al. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem 2009; 284: 26085–26095.
9. O'Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol 2004; 121: 254–263.
10. Sanderson RD, Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 2008; 25: 149–159.
11. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002; 100:610–617.
12. Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005; 105: 1303–1309.
13. Ridley RC, Xiao HQ, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993; 81: 767–774.
14. Wu YH, Yang CY, Chien WL, Lin KI, Lai MZ. Removal of syndecan-1 promotes TRAIL-induced apoptosis in myeloma cells. J Immunol 2012; 188: 2914–2921.
15. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr. et al. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007; 282: 13326–13333.
16. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007; 109: 4914–4923.
17. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008; 283: 32628–32636.
18. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010; 115: 2449–2457.
19. Ramani VC, Pruett PS, Thompson CA, DeLucas LD, Sanderson RD. Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem 2012; 287: 9952–9961.
20. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003; 63: 8749–8756.
21. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000; 95: 388–392.
22. Scudla V, Pika T, Budikova M, Petrova J, Minarik J, Bacovsky J et al. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma 2010; 57: 102–110.
23. Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol 1997; 99: 368–371.
24. Rapraeger AC. Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-alphavbeta3 integrin complex in tumorigenesis and angiogenesis. FEBS J 2013; 280: 2207–2215.
25. Wang H, Jin H, Rapraeger AC. Syndecan-1 and syndecan-4 capture epidermal growth factor receptor family members and the alpha3beta1 integrin via binding sites in their ectodomains: novel synstatins prevent kinase capture and inhibit alpha6beta4-integrin-dependent epithelial cell motility. J Biol Chem 2015; 290: 26103–26113.
26. Beauvais DM, Rapraeger AC. Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. J Cell Sci 2010; 123: 3796–3807.
27. McQuade KJ, Beauvais DM, Burbach BJ, Rapraeger AC. Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts. J Cell Sci 2006; 119: 2445–2456.
28. Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 2009; 206: 691–705.
29. Sanz-Rodriguez F, Ruiz-Velasco N, Pascual-Salcedo D, Teixido J. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br J Haematol 1999; 107: 825–834.
30. Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis 2008; 25: 325–334.
31. Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L et al. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 2003; 17: 1015–1025.
32. Sotnikov I, Hershkoviz R, Grabovsky V, Ilan N, Cahalon L, Vlodavsky I et al. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol 2004; 172: 5185–5193.
33. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C et al. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 2009; 69: 1758–1767.
34. Riaz A, Ilan N, Vlodavsky I, Li JP, Johansson S. Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J Biol Chem 2013; 288: 12366–12375.
35. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 2011; 17: 1382–1393.
36. Pisano C, Vlodavsky I, Ilan N, Zunino F. The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol 2014; 89: 12–19.
37. Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol 2013; 85: 1424–1432.
38. Ramani VC, Yang Y, Ren Y, Nan L, Sanderson RD. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem 2011; 286: 6490–6499.
39. Desai UR, Wang HM, Linhardt RJ. Specificity studies on the heparin lyases from Flavobacterium heparinum. Biochem 1993; 32: 8140–8145.
40. Ridley AJ. Life at the leading edge. Cell 2011; 145: 1012–1022.
41. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G et al. Cell migration: integrating signals from front to back. Science 2003; 302: 1704–1709.
42. Wang H, Leavitt L, Ramaswamy R, Rapraeger AC. Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. J Biol Chem 2010; 285: 13569–13579.
43. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res 2007; 100: 782–794.
44. Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 2000; 96: 2528–2536.
45. Yang Y, Borset M, Langford JK, Sanderson RD. Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface. J Biol Chem 2003; 278: 12888–12893.
46. Massia SP, Hubbell JA. Vascular endothelial cell adhesion and spreading promoted by the peptide REDV of the IIICS region of plasma fibronectin is mediated by integrin alpha 4 beta 1. J Biol Chem 1992; 267: 14019–14026.
47. Sheppard AM, Onken MD, Rosen GD, Noakes PG, Dean DC. Expanding roles for alpha 4 integrin and its ligands in development. Cell Adhes Commun 1994; 2: 27–43.
48. Garmy-Susini B, Avraamides CJ, Schmid MC, Foubert P, Ellies LG, Barnes L et al. Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res 2010; 70: 3042–3051.
49. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008; 8: 604–617.
50. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025–2031.
51. Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 2003; 17: 1961–1966.
52. Martinelli G, Tosi P, Ottaviani E, Soverini S, Tura S. Molecular therapy for multiple myeloma. Haematologica 2001; 86: 908–917.
53. Orecchia P, Conte R, Balza E, Pietra G, Mingari MC, Carnemolla B. Targeting syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Oncotarget 2015; 6: 37426–37442.
54. Orecchia P, Conte R, Balza E, Petretto A, Mauri P, Mingari MC et al. A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. Eur J Cancer 2013; 49: 2022–2033.
55. Lamorte S, Ferrero S, Aschero S, Monitillo L, Bussolati B, Omede P et al. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia 2012; 26: 1081–1090.
56. Feral CC, Rose DM, Han J, Fox N, Silverman GJ, Kaushansky K et al. Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. J Clin Invest 2006; 116: 715–723.
57. Goldfinger LE, Han J, Kiosses WB, Howe AK, Ginsberg MH. Spatial restriction of alpha4 integrin phosphorylation regulates lamellipodial stability and alpha4beta1-dependent cell migration. J Cell Biol 2003; 162: 731–741.
58. Han J, Rose DM, Woodside DG, Goldfinger LE, Ginsberg MH. Integrin alpha 4 beta 1-dependent T cell migration requires both phosphorylation and dephosphorylation of the alpha 4 cytoplasmic domain to regulate the reversible binding of paxillin. J Biol Chem 2003; 278: 34845–34853.
59. Kil SH, Krull CE, Cann G, Clegg D, Bronner-Fraser M. The alpha4 subunit of integrin is important for neural crest cell migration. Dev Biol 1998; 202: 29–42.
60. Tzima E, Del Pozo MA, Kiosses WB, Mohamed SA, Li S, Chien S et al. Activation of Rac1 by shear stress in endothelial cells mediates both cytoskeletal reorganization and effects on gene expression. EMBO J 2002; 21: 6791–6800.
61. Tzima E, del Pozo MA, Shattil SJ, Chien S, Schwartz MA. Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. EMBO J 2001; 20: 4639–4647.
62. Alon R, Feigelson SW, Manevich E, Rose DM, Schmitz J, Overby DR et al. Alpha4beta1-dependent adhesion strengthening under mechanical strain is regulated by paxillin association with the alpha4-cytoplasmic domain. J Cell Biol 2005; 171: 1073–1084.
63. Goldfinger LE, Tzima E, Stockton R, Kiosses WB, Kinbara K, Tkachenko E et al. Localized alpha4 integrin phosphorylation directs shear stress-induced endothelial cell alignment. Circ Res 2008; 103: 177–185.
64. Han J, Liu S, Rose DM, Schlaepfer DD, McDonald H, Ginsberg MH. Phosphorylation of the integrin alpha 4 cytoplasmic domain regulates paxillin binding. J Biol Chem 2001; 276: 40903–40909.
65. Nishiya N, Kiosses WB, Han J, Ginsberg MH. An alpha4 integrin-paxillin-Arf-GAP complex restricts Rac activation to the leading edge of migrating cells. Nat Cell Biol 2005; 7: 343–352.
66. Stewart M, Hogg N. Regulation of leukocyte integrin function: affinity vs. avidity. J Cell Biochem 1996; 61: 554–561.
67. Jin ZG, Ueba H, Tanimoto T, Lungu AO, Frame MD, Berk BC. Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res 2003; 93: 354–363.
68. Chen KD, Li YS, Kim M, Li S, Yuan S, Chien S et al. Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc. J Biol Chem 1999; 274: 18393–18400.
69. Wang Y, Miao H, Li S, Chen KD, Li YS, Yuan S et al. Interplay between integrins and FLK-1 in shear stress-induced signaling. Am J Physiol Cell Physiol 2002; 283: C1540–C1547.
70. Conway D, Schwartz MA. Lessons from the endothelial junctional mechanosensory complex. F1000 Biol Rep 2012; 4: 1.
71. Rapraeger AC, Ell BJ, Roy M, Li X, Morrison OR, Thomas GM et al. Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between alphaVbeta3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis. FEBS J 2013; 280: 2194–2206.
72. McFall AJ, Rapraeger AC. Identification of an adhesion site within the syndecan-4 extracellular protein domain. J Biol Chem 1997; 272: 12901–12904.
73. McFall AJ, Rapraeger AC. Characterization of the high affinity cell-binding domain in the cell surface proteoglycan syndecan-4. J Biol Chem 1998; 273: 28270–28276.
74. Whiteford JR, Ko S, Lee W, Couchman JR. Structural and cell adhesion properties of zebrafish syndecan-4 are shared with higher vertebrates. J Biol Chem 2008; 283: 29322–29330.
75. Whiteford JR, Behrends V, Kirby H, Kusche-Gullberg M, Muramatsu T, Couchman JR. Syndecans promote integrin-mediated adhesion of mesenchymal cells in two distinct pathways. Exp Cell Res 2007; 313: 3902–3913.
76. Whiteford JR, Couchman JR. A conserved NXIP motif is required for cell adhesion properties of the syndecan-4 ectodomain. J Biol Chem 2006; 281: 32156–32163.
77. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14: 2519–2526.
78. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 2000; 38: 71–81.
79. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658–1667.
80. Schmidmaier R, Morsdorf K, Baumann P, Emmerich B, Meinhardt G. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int J Biol Markers 2006; 21: 218–222.
81. Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab 2009; 27: 16–23.
82. Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000; 96: 1953–1960.
83. Shishido S, Bonig H, Kim YM. Role of integrin alpha4 in drug resistance of leukemia. Front Oncol 2014; 4: 99.
84. Rapraeger A, Jalkanen M, Endo E, Koda J, Bernfield M. The cell surface proteoglycan from mouse mammary epithelial cells bears chondroitin sulfate and heparan sulfate glycosaminoglycans. J Biol Chem 1985; 260: 11046–11052.
85. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38: 2018–2039.
86. Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron 2012; 5: 115–132.
87. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med 2007; 11: 427–452.
88. Meirovitz A, Hermano E, Lerner I, Zcharia E, Pisano C, Peretz T et al. Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 2011; 71: 2772–2780.
89. Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoreto M et al. Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med 2011; 15: 1857–1864.
90. Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007; 33: 557–568.
91. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009; 50: 958–968.
92. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS ONE 2011; 6: e21106.
93. Hammond E, Brandt R, Dredge K. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS ONE 2012; 7: e52175.
94. Beauvais DM, Burbach BJ, Rapraeger AC. The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol 2004; 167: 171–181.
95. Beauvais DM, Rapraeger AC. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2004; 2: 3.
96. Allen BL, Rapraeger AC. Spatial and temporal expression of heparan sulfate in mouse development regulates FGF and FGF receptor assembly. J Cell Biol 2003; 163: 637–648.
97. Jalkanen M, Nguyen H, Rapraeger A, Kurn N, Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells: localization on the cell surface with a monoclonal antibody. J Cell Biol 1985; 101: 976–984.
98. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683–690.
99. Lebakken CS, Rapraeger AC. Syndecan-1 mediates cell spreading in transfected human lymphoblastoid (Raji) cells. J Cell Biol 1996; 132: 1209–1221.
100. Lebakken CS, McQuade KJ, Rapraeger AC. Syndecan-1 signals independently of beta1 integrins during Raji cell spreading. Exp Cell Res 2000; 259: 315–325.